Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of patients with progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors. The company also offers COTELLIC, an inhibitor of MEK as a combination regimen to treat advanced melanoma; and MINNEBRO, an oral non-steroidal selective blocker of the mineralocorticoid receptor for the treatment of hypertension in Japan. Exelixis, Inc. has collaboration and license agreement with Ipsen Pharma SAS, Genentech, Inc., GlaxoSmithKline, Bristol-Myers Squibb Company, Merck, Invenra, Inc., StemSynergy Therapeutics, Inc., and Daiichi Sankyo Company, Limited. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was founded in 1994 and is headquartered in Alameda, California.
Industry, Sector and Symbol
Industry Commercial physical research
Sub-IndustryBiotechnology
SectorMedical
Phone650-837-7000
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$853.83 million
Profitability
Miscellaneous
Employees484
Next Earnings Date5/1/2019 (Estimated)
OptionableOptionable
Exelixis (NASDAQ:EXEL) Frequently Asked Questions
What is Exelixis' stock symbol?
Exelixis trades on the NASDAQ under the ticker symbol "EXEL."
How were Exelixis' earnings last quarter?
Exelixis, Inc. (NASDAQ:EXEL) posted its earnings results on Tuesday, February, 12th. The biotechnology company reported $0.37 EPS for the quarter, beating the Zacks' consensus estimate of $0.23 by $0.14. The biotechnology company had revenue of $228.60 million for the quarter, compared to the consensus estimate of $188.44 million. Exelixis had a return on equity of 48.90% and a net margin of 80.95%. The company's revenue for the quarter was up 90.4% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.12 earnings per share. View Exelixis' Earnings History.
When is Exelixis' next earnings date?
What price target have analysts set for EXEL?
10 brokerages have issued 1-year price objectives for Exelixis' shares. Their predictions range from $22.00 to $48.00. On average, they anticipate Exelixis' stock price to reach $29.10 in the next year. This suggests a possible upside of 19.2% from the stock's current price. View Analyst Price Targets for Exelixis.
What is the consensus analysts' recommendation for Exelixis?
10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Exelixis in the last year. There are currently 4 hold ratings and 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Exelixis.
Has Exelixis been receiving favorable news coverage?
News stories about EXEL stock have been trending somewhat positive this week, according to InfoTrie Sentiment. InfoTrie ranks the sentiment of press coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Exelixis earned a daily sentiment score of 1.7 on InfoTrie's scale. They also assigned media stories about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the stock's share price in the next several days.
Are investors shorting Exelixis?
Exelixis saw a decrease in short interest in the month of February. As of February 28th, there was short interest totalling 15,548,003 shares, a decrease of 8.8% from the February 15th total of 17,054,642 shares. Based on an average daily trading volume, of 3,134,824 shares, the short-interest ratio is currently 5.0 days. Currently, 5.3% of the shares of the stock are short sold. View Exelixis' Current Options Chain.
Who are some of Exelixis' key competitors?
Some companies that are related to Exelixis include Iqvia (IQV), Incyte (INCY), EXACT Sciences (EXAS), Icon (ICLR), PRA Health Sciences (PRAH), Charles River Laboratories Intl. (CRL), Syneos Health (SYNH), BTG (BTGGF), Medpace (MEDP), Intrexon (XON), Eloxx Pharmaceuticals (ELOX), Sorrento Therapeutics (SRNE), STARPHARMA HOLD/S (SPHRY), Pieris Pharmaceuticals (PIRS) and Anavex Life Sciences (AVXL).
What other stocks do shareholders of Exelixis own?
Who are Exelixis' key executives?
Exelixis' management team includes the folowing people:
- Dr. Stelios Papadopoulos, Co-Founder & Chairman (Age 71)
- Dr. Michael M. Morrissey, CEO, Pres & Director (Age 58)
- Mr. Christopher J. Senner, Exec. VP & CFO (Age 51)
- Dr. Peter Lamb, Exec. VP of Scientific Strategy & Chief Scientific Officer (Age 58)
- Mr. Jeffrey J. Hessekiel, Exec. VP, Gen. Counsel & Sec. (Age 50)
Who are Exelixis' major shareholders?
Exelixis' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (10.23%), FMR LLC (7.13%), First Trust Advisors LP (1.86%), Bank of New York Mellon Corp (1.25%), Geode Capital Management LLC (1.01%) and Geode Capital Management LLC (1.01%). Company insiders that own Exelixis stock include Alan M Garber, Carl B Feldbaum, Charles Cohen, Christopher J Senner, George A Scangos, George Poste, Gisela Schwab, Jack L Wyszomierski, Jeffrey Hessekiel, Lance Willsey, Michael Morrissey, Patrick J Haley, Stelios Papadopoulos and Vincent T Marchesi. View Institutional Ownership Trends for Exelixis.
Which institutional investors are selling Exelixis stock?
EXEL stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Millennium Management LLC, American Century Companies Inc., D. E. Shaw & Co. Inc., Rhenman & Partners Asset Management AB, Tekla Capital Management LLC, Los Angeles Capital Management & Equity Research Inc. and Hsbc Holdings PLC. Company insiders that have sold Exelixis company stock in the last year include Alan M Garber, Carl B Feldbaum, Charles Cohen, Christopher J Senner, George A Scangos, Gisela Schwab, Jeffrey Hessekiel, Lance Willsey, Michael Morrissey, Patrick J Haley, Stelios Papadopoulos and Vincent T Marchesi. View Insider Buying and Selling for Exelixis.
Which institutional investors are buying Exelixis stock?
EXEL stock was bought by a variety of institutional investors in the last quarter, including Norges Bank, Oregon Public Employees Retirement Fund, Fiera Capital Corp, Prudential Financial Inc., First Trust Advisors LP, Samlyn Capital LLC, Bank of New York Mellon Corp and Frontier Capital Management Co. LLC. View Insider Buying and Selling for Exelixis.
How do I buy shares of Exelixis?
Shares of EXEL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Exelixis' stock price today?
One share of EXEL stock can currently be purchased for approximately $24.41.
How big of a company is Exelixis?
Exelixis has a market capitalization of $7.33 billion and generates $853.83 million in revenue each year. The biotechnology company earns $690.07 million in net income (profit) each year or $1.43 on an earnings per share basis. Exelixis employs 484 workers across the globe.
What is Exelixis' official website?
How can I contact Exelixis?
Exelixis' mailing address is 1851 Harbor Bay Parkway, Alameda CA, 94502. The biotechnology company can be reached via phone at 650-837-7000 or via email at [email protected]
MarketBeat Community Rating for Exelixis (NASDAQ EXEL)
MarketBeat's community ratings are surveys of what our community members think about Exelixis and other stocks. Vote "Outperform" if you believe EXEL will outperform the S&P 500 over the long term. Vote "Underperform" if you believe EXEL will underperform the S&P 500 over the long term. You may vote once every thirty days.
